GlassScriptPhysician profile
Anna Karagyan
NPI 1750165684
$480.70
in general payments reported to CMS, 2019-2025
13 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $240 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $480.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $133.43 | 2024-2025 | |
| Hologic Sales and Service, LLC | $69.94 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Sanofi-Aventis U.S. LLC | $41.43 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $28.89 | 2025 | Dupixent |
| Ardelyx, INC. | $28.15 | 2025 | Ibsrela |
| Krystal Biotech INC | $27.39 | 2024 | Vyjuvek |
| Aimmune Therapeutics, INC. | $25.95 | 2024 | |
| Glaxosmithkline, LLC. | $23.93 | 2024 | Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $23.78 | 2024 | |
| Sumitomo Pharma America, INC. | $23.36 | 2025 | Gemtesa |
| Novo Nordisk INC | $21.74 | 2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $18.89 | 2024 | Mounjaro |
| Phadia US INC. | $13.82 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Karagyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.